Project Grant R44CA302066
Award Date 8/18/25
Completion Date 7/31/27
Dollars Obligated $1.2M
Federal Agency
Awardee
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
- This federal Project Grant award of $406,500.00, provided by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research), supports the development and evaluation of a novel, targeted small molecule inhibitor called TRE-515 to improve outcomes for patients with non-small-cell lung cancer (NSCLC). The recipient, Trethera Corp, is a clinical-stage biopharmaceutical company that is currently investigating TRE-515 in a Phase 1a open-label, dose escalation study in patients with solid...
- This Project Grant award, provided by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research), aims to develop a targeted therapy for the treatment of metastatic castration-resistant prostate cancer (mCRPC). The $571,271 award, granted on April 15, 2025, will fund research to create a drug conjugate that combines the PSMA-targeting small molecule PSMA-617 with the microtubule inhibitor monomethyl auristatin E (MMAE) and a custom macrocyclic linker. This novel targeted therapy...
- This $353,009 Project Grant awarded by the National Cancer Institute (NCI), under the Cancer Treatment Research program (CFDA 93.395), supports the development of novel multivalent PSMA-targeted taxane-conjugate therapeutics for treating bone metastases in prostate cancer. The primary awardee, Paramita Therapeutics Inc., a small disadvantaged business located in San Diego, California, will synthesize and evaluate these targeted drug-conjugates, which aim to selectively deliver taxane...
- This $398,728 Project Grant awarded by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) supports the development of a novel homologous recombination (HR) inhibitor, CP-8, to sensitize triple-negative breast cancer (TNBC) cells to DNA-damaging agents. The project aims to examine the synergy of CP-8 with various DNA-damaging therapies, including PARP inhibitors and ionizing radiation, in TNBC cell lines, patient-derived xenograft models, and in vivo...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding of $799,962 to Tripill Biotechnology, Corp. to develop radiolabeled PSMA agents with low salivary gland uptake for improved prostate cancer imaging and therapy. The key products and services to be delivered include: Constructing PSMA derivative compounds, such as NOTA-UNC-PSMA2, that can selectively reduce salivary gland uptake while maintaining high tumor uptake in prostate...
- This $2,895,540 federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to Duke University will support research to understand and target epigenetic regulation of immune evasion in prostate cancer. The research aims to investigate the role of the epigenetic regulator TNRC18 in shaping the tumor immune microenvironment and sensitizing prostate cancer to immune checkpoint inhibitor therapy. The 4-year project will utilize human and mouse prostate...
- This $177,209 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to develop innovative chemical probes targeting the "undruggable" protein c-Myc to treat castration-resistant prostate cancer (CRPC). The primary performer, Temple University, will apply its proprietary Fluorine-Thiol Displacement Reaction (FTDR) stapling technology to rationally design peptide mimetics that can effectively inhibit c-Myc activity and AR signaling in...
- This Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $185,760 to The Regents of the University of California, San Francisco (UCSF) to develop a novel combination therapy for treating metastatic castration-resistant prostate cancer (mCRPC). The project aims to co-deliver an antibody-drug conjugate (containing the cytotoxic agent monomethyl auristatin E) and the radioactive isotope actinium-225 directly to cancer cells. This synergistic...
- The National Cancer Institute (NCI) awarded a $1,022,522 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to Isoprene Pharmaceuticals Inc. (UEI: KS62EAD1NHJ7) for the "Development of VNPP433-3beta as Novel Therapeutic for All Stages of Prostate Cancer". This 2-year grant, with an initial award date of June 4, 2025, supports the development of a novel prostate cancer drug candidate, VNPP433-3beta, that targets both tumor growth and metastasis. The research aims to...
- This $267,298 Project Grant awarded by the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) to Dana-Farber Cancer Institute, Inc. (Dfci) supports research to target the CDK4/6 pathway in translocation renal cell carcinoma (TRCC), an aggressive form of kidney cancer. The project aims to test the hypothesis that inhibiting the CDK4/6 pathway, either alone or in combination with targeting the PI3K/mTOR pathway, may be an effective therapeutic strategy for TRCC. Through in vitro and...